Compare EXPE & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPE | KVUE |
|---|---|---|
| Founded | 1996 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Specialty Chemicals |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5B | 36.9B |
| IPO Year | 2005 | 2023 |
| Metric | EXPE | KVUE |
|---|---|---|
| Price | $303.14 | $18.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 11 |
| Target Price | ★ $275.89 | $19.45 |
| AVG Volume (30 Days) | 1.4M | ★ 18.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | 0.77% | ★ 4.82% |
| EPS Growth | 9.61 | ★ 40.74 |
| EPS | ★ 7.05 | 0.48 |
| Revenue | $14,733,000,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $10.35 | $4.85 |
| Revenue Next Year | $6.93 | $2.63 |
| P/E Ratio | $43.69 | ★ $39.84 |
| Revenue Growth | ★ 7.61 | N/A |
| 52 Week Low | $185.34 | $14.02 |
| 52 Week High | $342.00 | $20.69 |
| Indicator | EXPE | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 48.31 |
| Support Level | $271.13 | $18.67 |
| Resistance Level | $336.66 | $19.15 |
| Average True Range (ATR) | 11.77 | 0.31 |
| MACD | -4.97 | -0.03 |
| Stochastic Oscillator | 6.63 | 33.53 |
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of 2025 sales), air tickets (3%), rental cars, cruises, in-destination, and other (9%), and advertising revenue (8%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and alternative accommodations brand Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.